clinical trial · NCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Alexion Pharmaceuticals, Inc.·phase2·recruiting·n = 91
Relapsed AL AmyloidosisRefractory AL AmyloidosisLight Chain AmyloidosisAmyloidosisAZD0120
brief summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
started
Aug 18, 2025
primary completion
Aug 15, 2029
completion
Feb 14, 2031
last updated
Mar 24, 2026
official title
A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol